Crossmark

PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative “triplet” for oligometastatic hormone sensitive prostate cancer patients

Crossref DOI link: https://doi.org/10.1007/s12032-023-02268-3

Published Online: 2023-12-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Francolini, Giulio https://orcid.org/0000-0002-1784-7203
Porreca, Angelo

Facchini, Gaetano

Santini, Daniele

Bruni, Alessio

Simoni, Nicola

Trovò, Marco

Osti, Mattia Falchetto

Fornarini, Giuseppe

Sisani, Michele

Di Cataldo, Vanessa

Detti, Beatrice

Garlatti, Pietro

Bertini, Niccolò

Serni, Sergio

Minervini, Andrea

Livi, Lorenzo
License Information

Text and Data Mining valid from 2023-12-29

Version of Record valid from 2023-12-29
More Information

Article History

Received: 24 October 2023

Accepted: 22 November 2023

First Online: 29 December 2023

Declarations

:

: The authors have not disclosed any competing interests.

Document is current

Any future updates will be listed below